BOLDTIL™ 500

Cefuroxime Axetil 500mg operates through the same mechanism as its 250mg counterpart but delivers twice the systemic drug exposure, making it appropriate for moderate-to-severe infections requiring higher tissue drug concentrations. As a prodrug, cefuroxime axetil is hydrolysed at the intestinal brush border to release active cefuroxime, achieving higher peak plasma concentrations (Cmax) and greater area under the curve (AUC) compared to the 250mg dose.

Cefuroxime's bactericidal mechanism involves high-affinity binding to penicillin-binding proteins (PBPs) — the transpeptidase and carboxypeptidase enzymes responsible for peptidoglycan cross-linking in the bacterial cell wall. By irreversibly inhibiting PBP1 and PBP2, cefuroxime prevents cell wall biosynthesis, resulting in osmotic instability and bacterial lysis.

At the 500mg dose, cefuroxime achieves plasma concentrations well above the minimum inhibitory concentration (MIC) for the vast majority of susceptible organisms for the full interdose interval. For pathogens where the 250mg dose may produce borderline tissue concentrations — such as in pulmonary parenchyma, bone, or deep soft tissue — the 500mg dose provides the pharmacokinetic security margin needed for reliable clinical cure.

BOLDTIL™ 500 is indicated for moderate-to-severe bacterial infections requiring higher systemic cefuroxime concentrations, and for specific guideline-recommended indications where 500mg twice daily is the standard of care.

Community-Acquired Pneumonia: Moderate severity pneumonia in the outpatient setting. Covers S. pneumoniae, H. influenzae, M. catarrhalis, and S. aureus (MSSA). Guideline-recommended as step-down oral therapy following initial parenteral cephalosporin treatment.

Lyme Disease: 500mg twice daily for 14 to 21 days — the guideline-recommended oral regimen for early Lyme disease (erythema migrans). Particularly important where doxycycline is contraindicated.

Severe ENT Infections: Complicated sinusitis and deep-space ENT infections requiring higher tissue drug concentrations than the 250mg dose achieves.

Urinary Tract Infections: Complicated UTIs, acute uncomplicated pyelonephritis, and UTIs in pregnancy where a beta-lactam is preferred over fluoroquinolones.

Step-Down Therapy: Oral step-down following parenteral cephalosporin treatment of bacteraemia, osteomyelitis, and septic arthritis once clinical stabilisation is achieved.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.